• Explore /
  • Poster
  • / EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372).

EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372).

Abstract Poster

Authors

null

Mary E.R. O'Brien

The Royal Marsden Hospital, Surrey, United Kingdom

Mary E.R. O'Brien , Baktiar Hasan , Urania Dafni , Jessica Menis , Solange Peters , Michele De Waele , Rolf A. Stahel , Paul Van Schil , George Coukos , Sylvie Lantuejoul , Keith M. Kerr , Ignacio Melero , Benjamin Besse , Luis G. Paz-Ares

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT02504372

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS8571)

DOI

10.1200/JCO.2016.34.15_suppl.TPS8571

Abstract #

TPS8571

Poster Bd #

198b

Abstract Disclosures

Similar Posters

First Author: Kersti Oselin

First Author: Greg Andrew Durm

First Author: Christos Chouaid

First Author: Toon Van Gorp